Introduction
During the acute phase of a myocardial infarction (MI), ventricular arrhythmias are the principle cause of death. Indeed, nearly 70% of patients dying of an acute MI die suddenly prior to arriving to hospital (10) .
Safe and effective reduction in peri-MI arrhythmias is thus an essential strategy in improving peri-MI survival. Once a patient reaches hospital, a major goal of therapy is re-establishing cardiac perfusion in order to limit MI size. Once the MI is well established and the damage irreversible, it is important to limit adverse left ventricular (LV) remodeling in order to reduce the risk of heart failure (HF). Indeed, the extent of LV dilation is the most powerful predictor of long-term prognosis post-MI (22).
The acute phase of the MI is characterized by neurohumoral activation, a process that lasts for days then generally subsides over days to weeks, unless HF develops, in which case there is chronic progressive neurohumoral activation. The renin-angiotensin system, particularly angiotensin II (Ang II), is upregulated peri-and post-MI. Angiotensin receptor blockers (ARBs) have been shown to improve outcome when started early post-MI (21). One of the proposed mechanisms for these beneficial effects is improved LV remodeling (24), but other mechanisms are also possible (15) but not well worked out. It is uncertain as to what effect the presence (pre-treatment) of an ARB would have in the setting of an acute MI. One possibility is that it would exert a beneficial effect. In favor of this is a report of the ARB Losartan decreasing peri-MI arrhythmias during cardiac ischemia-reperfusion (28). However, it is also possible that they induce adverse effects due to excessive hypotension, as has been shown to occur with the ACEi Enalapril (26).
In the two studies that compared ARBs to ACEi therapy, drugs were initiated in small doses in order to avoid the adverse effects of excessive hypotension observed in the CONSENSUS II trial (26). The dose was then progressively increased. In the OPTIMAAL trial, the ARB did not perform as well as the ACEi (7) . One proposed hypothesis is that the dose of the ARB was inadequate (6) . Consistent with this hypothesis, a larger dose of an ARB was found to be equivalent to an ACEi in the VALIANT trial (21).
Thus, avoiding excessively high doses of an ARB early post-MI and assuring the use of higher doses later post-MI may be important in order to obtain the optimal effects of ARBs post-MI.
Thus, in the present study, we chose to mimic the proposed optimal clinical use of ARBs post-MI that is, starting with smaller known effective doses and progressively increasing to a high dose of the ARB losartan. We compared these effects to early and sustained high doses of losartan and to no treatment at all. We compared early (24 hour) post-MI ventricular arrhythmias, systemic blood pressure and survival, and late post-MI LV remodeling, function, MI size and fetal gene expression. We hypothesized that progressive doses of losartan would exert beneficial effects that would be superior both control and early a large doses of Losartan.
Materials and Methods

Animals and Drug-Regimen
Male Wistar rats (Charles River, St-Constant, Quebec, Canada) weighing 160-200 g were assigned to one of three groups: Losartan (Merck Frosst, Montreal, Qc) at 30mg/kg/day (High-dose) or 3mg/kg/day with an increase to 10mg/kg/day on day 10 post-MI, and to 30mg/kg/day on day 20 post-MI (progressivedose) or control. The low and high doses of Losartan were chosen based on a previous report demonstrating cardio-protective effects in rats following a MI (5, 24) . The increasing dose of Losartan over time post-MI was chosen to simulate the clinical situation where Losartan is started low and increased post-large-MI. Losartan was administered in drinking water starting 7 days prior to MI surgery.
In order to assure adequate levels of Losartan peri and early post-MI, it was administered by oral gavage, in high dose 15mg/kg (0.25ml) or low dose 1.5mg/kg (0.25ml) of Losartan or vehicle (0.9% saline) the evening after the MI and again twice the next day, after which the medication was once again administered in drinking water and continued for the duration of the specific protocol. All of the animal experiments followed the guidelines of the Canadian Council on Animal Care and were approved by the Animal Care Committee of the University Health Network (Toronto, ON).
Experimental Myocardial infarction
Rats were anaesthetized with an intra-muscular injection of a mixture of ketamine 50mg/kg (Rogar/STB, Montreal, Qc), and xylazine 10 mg/kg (Bayer Canada, Etobicoke, ON). MI was induced by ligation of the left anterior descending coronary artery as described previously by Nguyen et al. (19) . Sham operated rats underwent a similar procedure except the silk suture was not tied. Once awakened following surgery, the rats were injected with buprenorphine HCl 0.01 mg/kg as described previously.
Twenty-Four Hour Protocol: Ambulatory Electrocardiogram (ECG) and Blood Pressure Monitoring
Ten days prior to the MI, under ketamine and xylazine anesthesia, rats (n=48) had a transmitter implanted in the peritoneal cavity and anchored to the abdominal musculature. The implants had a pair of flexible stainless steel wires/leads (Data Sciences International, St-Paul, MN) implanted subcutaneoulsy for continuous ECG monitoring, and a blood pressure catheter, which was inserted into the descending aorta, as previously described (14) . The body of the implant that contains the electronics for signal handling and radio-transmission was placed in the peritoneal cavity. Rats were then housed in an individual cage placed on a receiver that continuously captures the radio-frequency signal from the transmitter and converts it into a serial bit stream (Dataquest A.R.T.2.2, DSI, St-Paul, Mn.). Ambient barometric pressure was also measured and subtracted from the telemetered pressure by data collection software to compensate for changes in atmospheric pressure.
Arrhythmia Analysis: Monitoring started 6-hours prior to MI until the time of death or 24-hours post-MI.
The observer classified all arrhythmic events on ambulatory electrocardiographic recordings according to the guidelines provided by The Lambeth Conventions and Curtis and Walker (4) with minor modifications as previously described by Lapointe et al (14) . The average arrhythmia score was calculated 6 h before MI, and for 4 post-MI time periods, 0-1 h, 1-6 h, 6-12 h, and 12-24 h.
Assessment of MI Size
Rats dying <4 hours post-MI were considered to have had a large-MI. Rats dying between 4 and 24-hours or surviving 24-hours post-MI had their hearts removed for determination of infarct size by triphenyl tetrazolium chloride (TTC). The LV was hand-cut into four slices before staining with TTC.
Tissue slices were stained by incubation in 1% TTC for 10 to 15 minutes at 37°C and pH 7.8. The tissue was then bathed for 15 minutes in a 10% formalin phosphate buffer to enhance color contrast. For each slice, the scarred area was photographed under a Leica M26 (Leica Microsystems Inc., Quebec, CA) and its surface was determined by planimetry (Labtronics Inc., Guelph, ON). Sections were traced on a calibrated digitizing tablet and morphologic variables calculated directly by computerized-planimetry with the Sigma Scan Pro software (Labtronics Inc., Guelph, Ontario, Canada).
Thirty-Eight Day Protocol:
454 male Wistar rats were randomly assigned into 3 groups: Losartan High-dose (30mg/kg/day) (n=103), Losartan Low-dose (3mg/kg/day increasing gradually to 30mg/kg/day) (n=161) or control (n=190), administered as described above (Figure 1 ).
To verify if the low dose of Losartan chosen blocked the Angiotensin (Ang) II signaling pathway, a doseresponse curve to AngII 6.5ng/kg to 650ng/kg (Sigma, Lot# 31K51142) was constructed in 16 rats treated with 3mg/kg/day of Losartan. The presser response to AngII was significantly attenuated for all doses of Ang II as compared with control (results not shown).
Echocardiographic measurements:
Thirty days post-MI, cardiac function and geometry were evaluated with an echocardiographic system equipped with a 15-MHz linear transducer (Acuson c256, Osiris Medical Inc., Toronto, ON). All studies were performed with rats anaesthetized with 2% halothane (Halocarbon Laboratories, Riveredge, NJ) using a vaporizer for halothane (Harvard Apparatus, Quebec, CA) and 0.2 l/min of oxygen. A comprehensive 2-dimensional study was performed for the measurement of the LV circumference and areas in both, systole and diastole. LV systolic diameter (LVSD), LV diastolic diameter (LVDD) were measured in the short-axis M-mode as previously described (14) .
Cardiac hemodynamic measurements
Thirty-eight days post-MI, rat were anesthetized with an intramuscular injection of ketamine (50 mg/kg), and xylazine (10 mg/kg) mixture. The LV and right ventricular (RV) pressures were measured by a Millar micro-tip catheter transducer, inserted into the right jugular vein and carotid artery and advanced to the RV and LV, respectively. Systolic and diastolic arterial pressures were measured in the aorta before being advanced to the LV. The maximum rate of pressure rise (+dP/dt) and decline (-dP/dt) were also measured. The pressures were recorded on a Gould 2600S recorder (Gould, Cleveland, OH). Once the hemodynamic measurements completed, rat were sacrificed and either used for assessment of LV remodeling by passive pressure-volume relationship, or morphologic assessment of cardiac hypertrophy.
Morphological Assessment of Cardiac Hypertrophy
In rats surviving to 38-days, the heart was removed, rapidly rinsed in saline solution, and dissected into atria, RV, LV, septum and scar. All portions of the heart, as well as the lungs, were then weighed individually and frozen at -80ºC. MI size was assessed by measuring the surface area of the scar. Prior to weighing, the scar was pinned on paper and its surface area measured by planimetry (Labtronics Inc., Guelph, ON). A large-MI was defined as an infarct size 0.8 cm 2 , a moderate MI was defined as an infarct size < 0.8 cm 2 and sham as no scar. A scar area of 0.8 cm 2 is equivalent to an MI of 35% of LV circumference in our experience (19) . Rats dying later than 24-hours post-MI but prior to hemodynamic monitoring had morphologic assessment for classification of MI size by assessing % of LV circumference infracted, as previously described (3), but were not used for other measurements, except for survival.
Passive Pressure-Volume Relationship and Ventricular Remodeling
Because the number of rats surviving the 38-days protocol in the high dose ARB group was low, only control and low-dose Losartan groups were used for this protocol. Hearts were removed after cardiac hemodynamic measurements, rinsed in a saline solution and then arrested in a supersaturated solution of KCL, after which passive pressure volume was assessed as previously described (3) . After the assessment of the pressure-volume relationship, the hearts were filled with saline to a pressure of 15mm
Hg, sealed and fixed in 10% formalin phosphate solution for 24-hours. The heart was then cut halfway between the base and apex, and 2 slices were obtained 1 mm above and below the middle cut and stained with hematoxylin-phloxine saffron for assessment of MI size as previously described (3) . Using this method, a large-MI was defined as those having a LV scar of 35% of the ventricular cross-sectional circumference, a moderate MI as having an LV scar<35%, and sham having no scar.
RNA Isolation and Purification
Total RNA was isolated from treated and untreated tissues from the septum of hearts, using TRIZOL method. RNA samples were further subjected to RNase-free DNase I treatment at 37 °C for 30 min, then purified with phenol chloroform and isoamyl alcohol, re-precipitated, and dissolved in nuclease-free water. RNA was quantified with GeneQuant spectrophotometer (Amersham Pharmacia Biotech, Piscataway, NJ) and RNA integrity was confirmed by running it on a formaldehyde gel. The isolated total RNA was used in real-time quantitative RT-PCR experiments. 
Real-Time Quantitative RT-PCR
Results
Survival
In the control group (n=190), 91 of 147 rats with a large-MI died within the first 24-hours (38.1% survival), and 16 died over the following 37 days, leaving 40 survivors (27.2%) at the end of the 38-day protocol. Of the rats receiving Losartan at 3mg/kg/day (n=161), 78 of 123 with a large-MI died within the first 24-hours (36.6% survival) and 4 died over the following 37 days, leaving 41 survivors (33.3%).
Of the rats receiving Losartan at 30mg/kg/day (n=103), 64 of 82 with a large-MI died within 24-hours (21.9% survival, p<0.01 vs. control and p<0.04 vs. Losartan low-dose). Of the remaining 18 rats, 7 died over the following 38-days, leaving only 11 survivors (13.4%, p<0.0001 vs. control and p<0.0001 vs.
Losartan low-dose) (figure 2A).
If one considers only rats with a large-MI that survived the first 24 h post-MI, over the following 37 days, the group receiving low-dose Losartan with a gradual increase in dose had the best survival, 91.5% as compared with 71.4% in the control group and 61.1% in Losartan high-dose (p<0.02 and p<0.01 respectively) (figure 2B).
24-Hour Protocol: Incidence and Duration of Ventricular Arrhythmias: (figure 3)
No VT or VF was recorded during the 6-hour baseline recording prior to coronary artery occlusion.
There was no difference in average ventricular arrhythmia score between large-MI control rats and large-MI rats receiving high-dose or low-dose Losartan.
Ambulatory Blood Pressure (figure 4A):
Mean arterial pressure (MAP) did not differ amongst the 3 treatment groups prior to Losartan administration, but it was significantly lower after 7 days of Losartan treatment in the 30mg/kg/day group. MAP decreased as a result of a large-MI in all 3 groups. Over the 24 hours post-MI period, MAP differed significantly across treatment groups. Planned pairwise comparisons revealed that following a large-MI, high dose treated animals had a lower MAP as compared to control and low-dose groups, p=0.05 and 0.02, respectively. Following a large-MI the MAP of rats receiving Losartan 3mg/kg/day did not significantly differ from those of control rats.
In high-dose Losartan rats with a large-MI that died in the first 24-hours post-MI, MAP was extremely low prior to death. As compared with controls and low-dose rats with equivalent MI size, MAP was lower over the 60-5 minutes time interval prior to death (both p<0.05), (figure 4B) suggesting that hypotension played a role in the death.
38-Day Protocol:
Echocardiographic Measurements (Table 1) In the sham-operated groups, Losartan in low or high-dose did not have a discernable effect on echocardiographic measurements. In control large-MI, there was significant LV dilatation with LV circumference and area in systole and diastole all increasing as compared to sham controls. There was also significant thinning of both the anterior and posterior walls, an increase in LV diastolic and systolic dimensions (LVDD and LVSD respectively), and impaired LV function as reflected by decreased LV shortening fraction (LVSF) and LV ejection fraction (LVEF).
Losartan high and low-doses had similar effects. Following a large-MI, they attenuated LV dilatation and helped preserve LV function as compared with control large-MI.
Hemodynamic Effects of Chronic Losartan Treatment (Table 2)
Thirty-eight days post-MI, in sham operated rats, in both Losartan groups (both were receiving 30 mg/kg/day at sacrifice) systolic and diastolic blood pressures were lower.
As compared with their sham counterparts, control large-MI rats had a decrease in LV systolic pressure (LVSP), an increase in LV end diastolic pressure (LVEDP) and a decrease in all measured indices of contractility and relaxation. These changes were accompanied by an increase in RV systolic pressure (RVSP) and RV end diastolic pressure (RVEDP).
Both groups of Losartan large-MI rats had similar hemodynamic changes. Systemic arterial pressure as well as LVSP decreased as compared with control animals with a large-MI. LVEDP, RVSP, and RVEDP all increased less suggesting improved LV function. LV +dP/dt when corrected for LVSP also improved as compared with control large-MI.
Morphological Measurements (Table 3)
In sham-operated rats, Losartan treatment had little effect, the only change being a reduction in LV mass in the high-dose Losartan group. As compared with their sham counterparts, control large-MI rats had a significant increase in RV, atrial and lung weights. In the two large-MI Losartan groups, the increase in RV, septal, atrial and lung weights were less marked than in control large-MI.
Passive LV Pressure-Volume Relationship
Losartan treatment exerted a significant effect on the passive pressure-volume relationship (p<0.02). In sham-operated rats, Losartan caused a slight leftward shift in the passive pressure-volume relationship.
A rightward shift in the passive pressure-volume relationships of all large-MI groups was observed, however the rightward shift was less in the Losartan treated rats ( Figure 5 )
MI Size
Animals with a large infarct surviving the 38-day protocol used for real-time PCR had similar infarct surface area, in the high dose group 1.05 ± 0.06 cm 2 (n= 11) as compared to 1.21 ± 0.04 cm 2 (n=31) and 1.24 ± 0.05 cm 2 (n=14) in non-treated and low-dose treated animals respectively (p >0.05). No difference in MI-size was also observed in animals who underwent passive LV pressure-volume assessment and had their MI size calculated via HPS staining and computer planimetry in the non-treated (n= 9) and low-dose treated (n=27) groups, 45.1 ± 1.8% vs. 41.6 ± 1.4% of the LV wall circumference, respectively, p=0.2.
Real-time PCR (Figure 6)
Losartan had no effect on LV target mRNA expression in sham-operated rats. In control-large-MI, there was a significant reduction in GLUT-4 mRNA expression, and an increase in fetal gene expression (SKACT, ANF, and -MHC mRNA) as compared to sham-operated rats. Both Losartan large-MI groups had significantly higher levels of GLUT-4 mRNA expression as compared to control large-MI, and LV SKACT, ANF, and -MHC mRNA expression were significantly less elevated than control large-MI.
Discussion:
The main findings of this study are 1) that the administration of the ARB Losartan in the pre-peri-and post-large-MI period does not result in improved 38-day post-MI survival, and that the administration of high-doses in the peri-MI period actually increases mortality due to excessive hypotension; 2) that 
Peri-MI effects of Losartan: concerns regarding hypotension:
In animals with a large-MI, higher dose of Losartan given peri-MI resulted in an increase in 24-hour post-MI mortality. Careful analysis of MAP in rats dying during the first 24-hours post-MI, revealed that rats receiving the higher dose of Losartan more frequently had marked hypotension the hour prior to death suggesting that hypotension contributed to their death. In these rats, MAP within 1-hour of dying ranged between 50 and 60 mmHg, much lower than the 75-90 mmHg in rats dying in the control and lower dose Losartan groups, suggesting a possible relationship between the hypotension caused by Losartan and increased mortality. Persistent hypotension post-MI is a serious concern since it has been linked to the occurrence of tachy-arrhythmias and ventricular fibrillation leading to sudden death (8) . It must nevertheless be noted that the lower dose of Losartan used in this study resulted in partial AT 1 receptor blockade as reflected by the rightward shift in Ang-II dose-response curve that it caused. In the CONSENSUS II trial, a high dose of the ACEi, Enalapril, started within the first 24-hours following an acute-MI resulted in a significantly higher incidence of hypotension and a trend towards increased mortality within 6 months following the initial infarction (26). Worrisome hypotension has also been reported in other clinical trials were ACE inhibition was initiated within the first day of a MI (1,2).
The idea of delaying therapy in order to reduce the onset of hypotension is a controversial one given that infarct expansion and remodeling is initiated within hours of a MI. In favor of an early aggressive approach is the HEART study by Pfeffer et al., where patients were randomized to early (within 24 hours) low dose Ramipril, early higher dose (progressive dose increase), and delayed Ramipril use. The low dose of Ramipril chosen for this study did not normally have hemodynamic effects, but did have mild hemodynamic effects in the acute MI setting (20) . Of the three treatment groups, the early high dose group had the best effects on LV remodeling suggesting that adequate doses of an ACEi early post MI is important. In the present study, the initial dose of losartan used, 3 mg/kg/day was proportionately greater than the dose used in the HEART study. In pilot studies we showed this dose to cause a significant rightward shift of the Ang-II dose-response relationship, and in a previous study, this dose that has been shown to have significant beneficial effects in the post-MI setting (4). The dose was then rapidly increased to 10 mg/kg/day, a larger dose also shown to be useful post-MI (12), and finally to 20 then 30 mg/kg/day. The results of the present study thus support the early use of lower doses of an ARB post-MI with up-titration to full doses early, as the HEART study did in with ACEi.
The findings of this study, contrast previous reports that have demonstrated beneficial outcomes with the use of ARBs administered pre-or early post-MI at doses similar to or higher than the 30mg/kg/day, used in this study. In a study by Zhu et al., the authors reported that pre-treatment with Losartan at 40mg/kg/day for 10 weeks followed by 17-minutes of ischemia and two hours of reperfusion (IR), resulted in decreased ventricular arrhythmias, decreased MI size, and decreased 2 hour post-MI mortality (28) . Surprisingly, the authors failed to show any hemodynamic modification with this high dose of Losartan. The explanation for these differences is not clear, but may have resulted from a combination of the experimental protocol (IR), the short follow-up period, and the anesthesia used in their study, our rats were awake and mobile most of the 24hour follow-up period. In another study, Ruzicka et al., who started Losartan treatment (15mg/kg/day) 3 days prior to MI and continued for 4 weeks post-MI, also did not report any early detrimental effects, but also did not report mortality following LAD ligation (23).
Effects of Losartan on Ventricular Arrhythmias:
Losartan was not found to modify ventricular arrhythmias during the first 24-hours post-MI in either low or high doses. In IR, results from Zhu et al would suggest that pre-treatment with Losartan at 40mg/kg/day, decreases ventricular arrhythmias in a rat model of IR (28). In another paper, the same group found that longer duration of pre-treatment (i.e. 4 weeks) was more cardio-protective than shorter periods (i.e. one week and one day) of pre-treatment prior to IR in rats (27), suggesting that longer pre-treatment in our study may have resulted in different findings. Alternatively, it may be that Losartan affects the arrhythmic properties in IR differently than it does in trans-mural MI, the mechanisms involved in both being quite different (17) . It may also be that the lack of hypotension associated with IR combined with high doses of Losartan is both necessary for its anti-arrhythmic effects to occur. In the study by Zhu et al, despite large doses, Losartan did not modify systolic blood pressure throughout the study (28), while in ours, the hypotension associated with the MI and high dose Losartan may have negated its anti-arrhythmic effects.
Beneficial post-MI effects of Losartan:
Losartan treatment in rats surviving the acute (24-hours) MI period with a low-dose, followed by timed, Alternatively, because no early harm could be documented acutely (<24-hours) with the lower dose, this lack of overall benefit may have resulted from inadequate sample size and power to detect a difference.
A study by Hu et al. has also reported that Losartan, at 10mg/kg/day; started early post-MI did not attenuate structural dilatation following coronary occlusion in rats (11) . At this time, no other study evaluating the peri-MI effects of an ARB exists to evaluate consistency with our results.
Limitations:
Animals were anesthetized at the time of surgery. This may have influenced arrhythmias and survival in the first two hours post-MI. Thereafter rats were awake and unrestrained for the next twenty-two hours of monitoring. A number of rats died during the study, which may have influenced hemodynamic measurements at the end of the study. In order to minimize problems related to loss of rats during the study, we classified rats according to MI size. Finally, because we did not include a low dose group without progressive up-titration, it is possible that it was unnecessary to progressively increase the dose.
This does not, however, change the clinical implications of our findings, that high doses of an ARB should be avoided early post-MI because they result in excessive hypotension and death. The combined results of the OPTIMAAL and VALIANT studies have established the need to up-titrate post-MI.
Conclusions:
This 
